Categories
| Category | |
|---|---|
| Health Conditions and Concerns | 40% |
| Medicine | 25% |
| Health | 15% |
| Others | 20% |
Explore sites in same category:
- ogorimii-med.net Rank 1.4M. Estimated value 1,512$
- ocrahope.org Rank 781.7K. Estimated value 2,760$
- myvision.org Rank 439.1K. Estimated value 4,932$
- gluten.org Rank 887.9K. Estimated value 2,424$
- veri.co Rank 646.5K. Estimated value 3,336$
- kesimpta.com Rank 1.3M. Estimated value 1,668$
- dr-hips.com Rank 1M. Estimated value 2,232$
- ito-jibika.net Rank 1.1M. Estimated value 1,968$
- presspogo.com Rank 663.9K. Estimated value 3,252$
- myeczemateam.com Rank 1.5M. Estimated value 1,392$
Keyword Suggestion
Domain Informations
Opdivo.com lookup results from whois.corporatedomains.com server:
- Domain created: 2012-11-06T02:19:18Z
- Domain updated: 2023-11-02T05:24:17Z
- Domain expires: 2024-11-06T02:19:18Z 0 Years, 192 Days left
- Website age: 11 Years, 172 Days
- Registrar Domain ID: 1757334616_DOMAIN_COM-VRSN
- Registrar Url: http://cscdbs.com
- Registrar WHOIS Server: whois.corporatedomains.com
- Registrar Abuse Contact Email: [email protected]
- Registrar Abuse Contact Phone: 8887802723
- Name server:
- NS1.BMS.COM
- NS2.BMS.COM
- NS3.BMS.COM
- NS4.BMS.COM
Network
- inetnum : 45.60.0.0 - 45.60.255.255
- name : INCAPSULA-NET
- handle : NET-45-60-0-0-1
- status : Direct Allocation
- created : 2010-09-15
- changed : 2023-02-27
Owner
- organization : Incapsula Inc
- handle : INCAP-5
- address : Array,Redwood Shores,CA,94065,US
Technical support
- handle : RIR7-ARIN
- name : rir
- phone : +1-650-345-9000
- email : [email protected]
Abuse
- handle : IMPER7-ARIN
- name : Imperva AbuseDesk
- phone : +1-866-250-7659
- email : [email protected]
| Domain Provider | Number Of Domains |
|---|---|
| godaddy.com | 286730 |
| namecheap.com | 101387 |
| networksolutions.com | 69118 |
| tucows.com | 52617 |
| publicdomainregistry.com | 39120 |
| whois.godaddy.com | 32793 |
| enomdomains.com | 23825 |
| namesilo.com | 21429 |
| domains.google.com | 21384 |
| cloudflare.com | 20573 |
| gmo.jp | 18110 |
| name.com | 17601 |
| fastdomain.com | 14708 |
| register.com | 13495 |
| net.cn | 12481 |
| ionos.com | 12416 |
| ovh.com | 12416 |
| gandi.net | 12305 |
| registrar.amazon.com | 12111 |
Host Informations
- IP address: 45.60.170.161
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
Site Inspections
Port Scanner (IP: 45.60.170.161)
Spam Check (IP: 45.60.170.161)
Websites Listing
We found Websites Listing below when search with opdivo.com on Search Engine
Healthcare Provider Resources | OPDIVO® (nivolumab)
Call 1-855-OPDIVO-1 (1-855-673-4861) 1-855-OPDIVO-1 (1-855-673-4861) to start the process. The initial phone call and any emails that may follow are to schedule a live appointment only. Your representative will discuss product information and answer your questions in person during the scheduled visit. Medical Inquiries and Reporting . Visit BMSmedinfo.com or call 1-800-721 …
Opdivohcp.comPerioperative Opdivo alone, in combination with Yervoy ...
2022-03-18 · Perioperative Opdivo alone, in combination with Yervoy safe in patients with HCC. By Georgia I Salvaryn. Source/Disclosures Published by: Source: Kaseb AO, et al. Lancet Gastroenterol Hepatol ...
Healio.comTranscenta, Bristol To Evaluate TST001 - Opdivo ...
1 day ago · As per the terms of the deal, Transcenta will be the sponsor of the trials and Bristol Myers Squibb will supply Opdivo to Transcenta for use in …
Nasdaq.comBristol-Myers Squibb Company (BMY-N) Quote - Press Release ...
In the Opdivo plus chemotherapy arm, patients received treatment with Opdivo 240 mg on Day 1 and Day 15, fluorouracil 800 mg/m²/day on Day 1 through Day …
Theglobeandmail.comIpsen: Cabometyx-Opdivo Showed Continued Survival, Quality ...
2022-02-15 · With a median follow-up of 32.9 months, Cabometyx in combination with Opdivo continued to show superiority across efficacy endpoints of overall survival, progression-free survival, objective ...
Nasdaq.comHIGHLIGHTS OF PRESCRIBING INFORMATION ...
• OPDIVO is indicated for the treatment of patients with metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. 1.4 . Malignant Pleural Mesothelioma . OPDIVO, in combination with …
Accessdata.fda.govOPDIVO - PLM
OPDIVO ® con ipilimumab: La media geométrica (CV%) de CL, Vss y de la vida media terminal de nivolumab fue de 10.0 mL/h (50.3%), 7.92 L (30.1%), y 24.8 días (94.3%), respectivamente. Cuando se administró en combinación, la CL de nivolumab se incrementó en un 24%, mientras que no se observó ningún efecto sobre la depuración de ipilimumab.
Medicamentosplm.com
Domains Expiration Date Updated
| Site | Provider | Expiration Date |
|---|---|---|
| redhouserh.com | godaddy.com | 172 Days |
| spyhackz.com | cloudflare.com | -1 Years, -277 Days |
| marketingmaestroz.com | publicdomainregistry.com | -1 Years, -345 Days |
| moviz-time.top | namecheap.com | -1 Years, -327 Days |
| santacruzdj.com | godaddy.com | -1 Years, -295 Days |
| kringlapp.com | namecheap.com | -2 Years, -86 Days |
| fynxther.com | ownregistrar.com | -1 Years, -278 Days |
| hipra.com | dinahosting.com | -1 Years, -204 Days |
| seseng.com | domains.google.com | -2 Years, -31 Days |
| chronicbuddha.com | godaddy.com | -2 Years, -46 Days |